Stress hyperglycemia and enhanced sensitivity to myocardial infarction

Current Hypertension Reports

Volumn 10, Issue 1, 2008, Pages 78-84

  Webster, Keith A ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; FRUCTOSE; GLUCOSE; HYDROCORTISONE; I KAPPA B KINASE BETA; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 6; MAMMALIAN TARGET OF RAPAMYCIN; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE; S6 KINASE; SYNAPTOPHYSIN; TUMOR NECROSIS FACTOR ALPHA;

ACUTE HEART INFARCTION; APOPTOSIS; CARBOHYDRATE DIET; CYTOKINE PRODUCTION; DISEASE MODEL; DISEASE PREDISPOSITION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; EVIDENCE BASED PRACTICE; GENE TRANSLOCATION; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE TRANSPORT; HEART INFARCTION SIZE; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HIGH FRUCTOSE DIET; HUMAN; HYDROCORTISONE RELEASE; HYPERGLYCEMIA; IMMUNOPATHOGENESIS; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INSULIN SENSITIVITY; MOLECULAR DYNAMICS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PROTEIN TARGETING; REPERFUSION INJURY; REVIEW; RISK ASSESSMENT; STRESS HYPERGLYCEMIA;

ACUTE DISEASE; ADAPTATION, PHYSIOLOGICAL; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERGLYCEMIA; INFLAMMATION; INSULIN RESISTANCE; MYOCARDIAL INFARCTION; OXIDATIVE STRESS; PROGNOSIS; RISK FACTORS;

EID: 39149083444     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-008-0015-0     Document Type: Review

References (53)

1. Umpierrez GE, Isaacs SD, Bazargan N, et al.: Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab 2002, 87:978-982.
2. Krinsley JS: Association between hyperglycemia and increased hospital mortality in a heterogeneous population of critically ill patients. Mayo Clin Proc 2003, 78:1471-1478.
3. Capes SE, Hunt D, Malmberg K, Gerstein HC: Stress hyperglycemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet 2000, 55:773-778.
4. Yudkin JS, Oswald GA: Hyperglycemia, diabetes and myocardial infarction. Diabetes Med 1987, 4:13-18.
5. Fava S, Aquilina O, Azzopardi J, et al.: The prognostic value of blood glucose in diabetic patients with acute myocardial infarction. Diabetes Med 1996, 13:80-83.
6. Malmberg K, Ryden L, Hamsten A, et al.: Mortality prediction in diabetic patients with myocardial infarction: experiences from the DIGAMI study. Cardiovasc Res 1997, 34:248-253.
7. Marik PE, Raghavan M: Stress-hyperglycemia, insulin and immunomodulation in sepsis. Intensive Care Med 2004, 30:748-756.
8. Van den Berghe G, Wouters R, Weekers F, et al.: Intensive insulin therapy in critically ill patients. N Engl J Med 2001, 345:1359-1367.
9. Suleiman M, Hammerman H, Boulos M, et al.: Fasting glucose is an important independent risk factor for 30-day mortality in patients with acute myocardial infarction: a prospective study. Circulation 2005, 111:754-760.
10. Aronson D, Hammerman H, Kapeliovich MR, et al.: Fasting glucose in acute myocardial infarction: incremental value for long-term mortality and relationship with left ventricular systolic function. Diabetes Care 2007, 30:960-966.
11. Zeller M, Cottin Y, Brindisi MC, et al.: Impaired fasting glucose and cardiogenic shock in patients with acute myocardial infarction. Eur Heart J 2004, 25:308-312.
12. Lee KL, Woodlief LH, Topol EJ, et al.: Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction: results from an international trial of 41,021 patients: GUSTO-I Investigators. Circulation 1995, 91:1659-1668.
13. Morrow DA, Antman EM, Charlesworth A, et al.: TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an Intravenous nPA for Treatment of Infarcting Myocardium Early II Trial Substudy. Circulation 2000, 102:2031-2037.
14. Pickup JC: Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 2004, 27:813-823.
15. Pickup JC: Inflammatory markers and type 2 diabetes. Diabetes Technol Ther 2006, 8:1-6.
16. Hu FB, Stampfer MJ, Haffner SM, et al.: Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care 2002, 25:1129-1134.
17. Schmidt MI, Duncan BB, Sharrett AR, et al.: Markers of inflammation and prediction of diabetes mellitus in adults: a cohort study. Lancet 1999, 353:1649-1652.
18. van den Berghe G: Neuroendocrine pathobiology of chronic illness. Crit Care Clin 2002, 18:509-528.
19. Mizock BA: Alterations in fuel metabolism in critical illness hyperglycemia. Best Pract Res Clin Endocrinol Metab 2001, 15:533-551.
20. Mehta VK, Hao W, Brooks-Worrell BM, Palmer JP: Low-dose interleukin 1 and tumor necrosis factor individually stimulate insulin release but in combination cause suppression. Eur J Endocrinol 1994, 130:208-214.
21. Esposito K, Nappo F, Marfella R, et al.: Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 2002, 106:16-23.
22. Esposito K, Marfella R, Giugliano D: Hyperglycemia and heart dysfunction: an oxidant mechanism contributing to heart failure in diabetes. J Endocrinol Invest 2002, 25:485-488.
23. Marfella R, Siniscalchi M, Esposito K, et al.: Effects of stress hyperglycemia on acute myocardial infarction: role of inflammatory immune process in functional cardiac outcome. Diabetes Care 2003, 26:3129-3135.
24. Esposito K, Marfella R, Giugliano D: Stress hyperglycemia, inflammation, and cardiovascular events. Diabetes Care 2003, 26:1650-1651.
25. Nishikawa T, Edelstein D, Du XL, et al.: Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000, 404:787-790.
26. Hummel KP, Dickie MM, Coleman DL: Diabetes, a new mutation in the mouse. Science 1996, 153:1127-1128.
27. Streamson SC, Chung WK, Wu-Peng S, et al.: Phenotypes of mouse diabetes and rat fatty due to mutations in the OB (leptin) receptor. Science 1996, 271:994-996.
28. Jones SP, Girod WG, Granger DN, et al.: Reperfusion injury is not affected by blockade of P-selectin in the diabetic mouse heart. Am J Physiol 1999, 277(2 Pt 2):H763-H769.
29. Greer JJ, Ware DP, Lefer DJ: Myocardial infarction and heart failure in the db/db diabetic mouse. Am J Physiol Heart Circ Physiol 2006, 290:H146-H153.
30. Thakker GD, Frangogiannis NG, Bujak M, et al.: Effects of diet-induced obesity on inflammation and remodeling after myocardial infarction. Am J Physiol Heart Circ Physiol 2006, 291:H2504-H2514.
31. Yue TL, Ban W, Gu JL, et al.: Rosiglitazone treatment in Zucker diabetic fatty rats is associated with ameliorated cardiac insulin resistance and protection from ischemia/reperfusion-induced myocardial injury. Diabetes 2005, 54:554-562.
32. Kersten JR, Montgomery MW, Ghassemi T, et al.: Diabetes and hyperglycemia impair activation of mitochondrial K(ATP) channels. Am J Physiol Heart Circ Physiol 2001, 280:H1744-H1750.
33. Backlund T, Palojoki E, Saraste A, et al.: Sustained cardiomyocyte apoptosis and left ventricular remodelling after myocardial infarction in experimental diabetes. Diabetologia 2004, 47:325-330.
34. Ravingerova T, Neckar J, Kolar F: Ischemic tolerance of rat hearts in acute and chronic phases of experimental diabetes. Mol Cell Biochem 2003, 249:167-174.
35. Marfella R, D'Amico M, Di Filippo C, et al.: Myocardial infarction in diabetic rats: role of hyperglycaemia on infarct size and early expression of hypoxia-inducible factor 1. Diabetologia 2002, 45:1172-1181.
36. Kaneto H, Katakami N, Kawamori D, et al.: Involvement of oxidative stress in the pathogenesis of diabetes. Antioxid Redox Signal 2007, 9:355-366.
37. Webster KA: Programmed death as a therapeutic target to reduce myocardial infarction. Trends Pharmacol Sci 2007, 28:492-499.
38. Draznin B: Molecular mechanisms of insulin resistance: serine phosphorylation of insulin receptor substrate-1 and increased expression of p85alpha: the two sides of a coin. Diabetes 2006, 55:2392-2397.
39. Qiao LY, Zhande R, Jetton TL, et al.: In vivo phosphorylation of insulin receptor substrate 1 at serine 789 by a novel serine kinase in insulin-resistant rodents. J Biol Chem 2002, 277:26530-26539.
40. Tzatsos A, Tsichlis PN: Energy depletion inhibits phosphatidylinositol 3-kinase/Akt signaling and induces apoptostis via AMP-activated protein kinase-dependent phosphorylation of IRS-1 at Ser-794. J Biol Chem 2007, 282:18069-18082.
41. Jakobsen SN, Hardie DC, Morrice N, Tornqvist HE: 5′-AMP-activated protein kinase phosphorylates IRS-1 on Ser-789 in mouse C2C12 myotubes in response to 5-aminoimidazole-4-carboxamide riboside. J Biol Chem 2001, 276:46912-46916.
42. Aguirre V, Uchida T, Yenush L, et al.: The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). J Biol Chem 2000, 275:9047-9054.
43. Hirosumi J, Tuncman G, Chang L, et al.: A central role for JNK in obesity and insulin resistance. Nature 2002, 420:333-336.
44. Bennett BL, Satoh Y, Lewis AJ: JNK: a new therapeutic target for diabetes. Curr Opin Pharmacol 2003, 3:420-425.
45. Jordan JE, Simandle SA, Tulbert CD, et al.: Fructose-fed rats are protected against ischemia/reperfusion injury. J Pharmacol Exp Ther 2003, 307:1007-1011
46. Kelley GL, Allan G, Azhar S: High dietary fructose induces a hepatic stress response resulting in cholesterol and lipid dysregulation. Endocrinology 2004, 145:548-555.
47. Wei Y, Pagliassotti MJ: Hepatospecific effects of fructose on c-Jun NH2-terminal kinase: implications for hepatic insulin resistance. Am J Physiol Endocrinol Metab 2004, 287:E926-E933.
48. Stanley WC, Recchia FA, Lopaschuk GD: Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 2005, 85:1093-1129.
49. Norhammar A, Tenerz A, Nilsson C, et al.: Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 2002, 359:2140-2144.
50. Bartnik M, Malmberg K, Hamsten A, et al.: Abnormal glucose tolerance-a common risk factor in patients with acute myocardial infarction in comparison with population-based controls. J Intern Med 2004, 256:288-297.
51. Bolk J, van der Ploeg T, Cornel JH, et al.: Impaired glucose metabolism predicts mortality after a myocardial infarction. Int J Cardiol 2001, 79:207-214.
52. Webster KA, Discher DJ, Bishopric NH: Regulation of fos and jun immediate-early genes by redox or metabolic stress in cardiac myocytes. Circ Res 1994, 74:679-686.
53. Khandoudi N, Delerive P, Berrebi-Bertrand I, et al.: Rosiglitazone, a peroxisome proliferator-activated receptor-gamma, inhibits the Jun NH(2)-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury. Diabetes 2002, 51:1507-1514.